PMS-LATANOPROST-TIMOLOL SOLUTION

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

TIMOLOL (TIMOLOL MALEATE); LATANOPROST

Boleh didapati daripada:

PHARMASCIENCE INC

Kod ATC:

S01ED51

INN (Nama Antarabangsa):

TIMOLOL, COMBINATIONS

Dos:

5MG; 50MCG

Borang farmaseutikal:

SOLUTION

Komposisi:

TIMOLOL (TIMOLOL MALEATE) 5MG; LATANOPROST 50MCG

Laluan pentadbiran:

OPHTHALMIC

Unit dalam pakej:

5ML

Jenis preskripsi:

Prescription

Kawasan terapeutik:

BETA-ADRENERGIC AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0248501002; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2013-04-10

Ciri produk

PRODUCT MONOGRAPH
PR
PMS-LATANOPROST-TIMOLOL
Fixed combination of latanoprost 50 mcg/mL and timolol 5 mg/mL as
timolol
maleate
STERILE OPHTHALMIC SOLUTION
ELEVATED INTRAOCULAR PRESSURE THERAPY
PROSTAGLANDIN F
2Α
ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue, Suite #100, March 28, 2017
Montréal, Québec
H4P 2T4
www.pharmascience.com
CONTROL NO: 194552
_ _
_ _
_pms-LATANOPROST-TIMOLOL Product Monograph Page 2 of 30 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTION
......................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
12
DOSAGE AND ADMINISTRATION
..............................................................................
13
OVERDOSAGE
................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 14
STORAGE AND STABILITY
.........................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 16
PART II: SCIENTIFIC INFORMATION
................................................................................
17
PHARMACEUTICAL INFORMATION
.........................................................................
17
CLINICAL T